Immuneering Corp
Immuneering Corp is listed today as Immuneering Corporation: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2025 | $25 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2020 | $37 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jan 2020 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2019 | $15 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Immuneering Corp chose not to state its revenue in its newest notice of a funding round (Sep 2025).
SEC Form D · Sep 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Sep 2025
That is all the official record says: Immuneering Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Immuneering Corp are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Benjamin J. Zeskind | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Biren Amin | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2021) | SEC Form 3 |
| Brett Matthew Hall | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Robert J. Carpenter | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Scott Barrett | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 67 investors.
Largest shareholders today
Institutions holding Immuneering Corporation shares, as of Sep 30, 2026.
- FMR LLC$38 M15.54%
- BlackRock, Inc.$20 M8.24%
- Sanofi$11 M4.58%
- Vanguard Capital Management LLC$9 M3.86%
- Geode Capital Management, LLC$6 M2.32%
- Price T Rowe Associates Inc /MD/$5 M2.09%
- State Street Corp$5 M1.95%
- Nuveen, LLC$4 M1.47%
- DCF Advisers, LLC$4 M1.46%
- Aberdeen Group plc$3 M1.33%
- Marshall Wace, LLP$3 M1.24%
- Goldman Sachs Group Inc$2 M1.03%
- Connor, Clark & Lunn Investment Management Ltd.$2 M0.98%
- Summit Financial, LLC$2 M0.80%
- Alethea Capital Management, LLC$2 M0.80%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Benjamin J. Zeskind | Executive officer | Sep 2025 |
| Benjamin J. Zeskind | Director | Sep 2025 |
| Diana F. Hausman | Director | Sep 2025 |
| Laurie B. Keating | Director | Sep 2025 |
| Peter J. Feinberg | Director | Sep 2025 |
| Robert J. Carpenter | Director | Sep 2025 |
| Thomas J. Schall | Director | Sep 2025 |
| Andrew J. Phillips | Director | Jan 2021 |
| Joseph J. Kekst | Director | Jan 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.